Clairvoyant Therapeutics Raises More Than $3 Million In Seed Financing, Adds Bench Strength To Senior Leadership Team
Clairvoyant Therapeutics Raises More Than $3 Million In Seed Financing, Adds Bench Strength To Senior Leadership Team
11/30/21, 8:00 AM
Location
vancouverMoney raised
$3 million
Round Type
seed
Clairvoyant Therapeutics, a Canadian biotech company focused on the development of psychedelic drug therapies for the treatment of addiction, is pleased to announce the Company has closed its initial financing round worth more than $3 million CAD. The bulk of the investment comes from four institutional investors including Iter Investments, Negev Capital, and Ambria Capital.
Company Info
Location
vancouver, washington, united states
Additional Info
Clairvoyant Therapeutics is a Canadian biotechnology company at the forefront of a growing psychedelic therapy industry and operates under the principles of open science. Our team has a successful track record designing and operating clinical trials for multiple therapeutic products and bringing new drugs to market.
Clairvoyant is committed to meeting the highest standards of verified social and environmental performance, public transparency and legal accountability to balance profit and purpose and is a pending B Corporation Certification.
Clairvoyant is a member of Life Science BC, an industry association that represents the scientific community of British Columbia at the local, national and international level.
For more information, please visit www.clairvoyantrx.com.
For more information:
Media requests:Marlo Taylor mtaylor@gagecommunications.ca
Corporate contact:Damian Kettlewell damian@clairvoyantrx.com